About Novo Holdings


We are a holding and investment company

Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation.

Established in 1999, Novo Holdings is the holding company of the Novo Group and manages the Foundation’s investment assets.

In addition to being the major shareholder in the Novo Group companies, Novo Holdings invests the wealth of the Foundation in two key categories: 1. Life Science Investments, which includes investing in life science companies at all stages of development; and 2. Financial Investments, which manages a diversified portfolio of equity and fixed income securities.

Working out of Copenhagen, with affiliates in San Francisco and Boston, Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

The purpose of the investments of Novo Holdings is both to grow the assets of the Foundation and to deliver a return that the Foundation can distribute for scientific, social and humanitarian purposes to improve the lives of people and the sustainability of society.

For more information, download our fact sheet.

We bring more than capital to life science companies in all stages of development Kasim Kutay, CEO, Novo Holdings

How we do business

At Novo Holdings, we aspire to a set of values that define the way we work. Our values underpin the Novo Holdings culture of high performance with high responsibility and long-term thinking.

  • We strive to deliver outstanding long-term results
  • Vision, collaboration and diversity are key to our performance
  • We conduct ourselves with integrity and transparency
  • We build long-term relationships based on trust and respect
  • Sustainability is integral to our business
  • Learning is core to our organization
  • Board of Directors

    The Board of Directors comprises six members each with a long and proven track record in investments or the life sciences.

  • Advisory Group

    The Novo Advisory Group is an expert panel that supports Novo Holdings in analysing the opportunities and risks associated with its larger investments.

  • Leadership team

    The leadership team of Novo Holdings comprises the CEO and the heads of the six departments.

Investments and transactions

  • 8.7 bn

    currently invested in the life science sector.

  • 300+

    life science investments since 1999.

Striving to improve the health and welfare of people

The Novo Nordisk Foundation awards grants for research, humanitarian and social purposes. The history of the Foundation dates back to 1922, when Professor and Nobel Laureate August Krogh and his wife, Marie, took a trip to North America and succeeded in acquiring the necessary knowledge and permission to manufacture insulin in Scandinavia. In return, August Krogh promised that profit from the sale of insulin would be returned to society as support for scientific and humanitarian purposes.

The production of insulin marked the beginning of the development of world-class diabetes medicine and a subsequent Danish business and export venture. It also led to the establishment of several foundations that, many years later, merged into today’s Novo Nordisk Foundation. From 2015-2019, the Foundation has awarded grants totalling DKK 20 billion.

Our location

Novo Holdings A/S
Tuborg Havnevej 19
2900 Hellerup
+45 3527 6500
CVR# 24257630

Novo Ventures (US) Inc.*
200 Clarendon Street, Floor 45
Boston, MA 02116

Novo Ventures (US) Inc.*
501 2nd Street, Suite 300
San Francisco, CA 94107
+1 (415) 552-6686

Media Relations
Christian Mostrup Scheel
Senior Press Officer
+45 3067 4805

*Novo Ventures (US) Inc. is a separate legal entity that provides certain consultancy services to Novo Holdings A/S, mainly within the areas of identifying, analysing and negotiating various investment opportunities among life science and biotech companies in the US as well as certain follow-up activities related thereto, such as board memberships, financial control and reporting efforts.